Tumor necrosis factor inhibitors

Details Tumor necrosis factor inhibitors Tumor necrosis factor inhibitors

1994-04-01

1996-01-23

Warden, Jill

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

25 or more amino acid residues in defined sequence

530325, 530326, 530327, 530328, 530329, 530330, C07K 500, C07K 700, C07K 1700

Patent

active

054865956

ABSTRACT:
Peptides which consist of 4-25 amino acids and which bind to tumor necrosis factor-alpha, prevent tumor necrosis factor-alpha from binding to its receptors and inhibit tumor necrosis factor-alpha activity are disclosed. Methods of inhibiting tumor necrosis factor-alpha activity and of treating individuals suffering from tumor necrosis factor-alpha-mediated diseases and disorders are disclosed.

REFERENCES:
Kohno et al PNAS, USA, vol. 87 p. 8331 (1990).
Gray et al PNAS, USA, vol. 87 p. 7380 (1990).
Eilat, D. et al., "V Region Sequences of Anti-DNA and Anti-RNA Autoantibodies form NZB/NZW F.sub.1 Mice", The J. of Immunol. 1988, 141, 1745-1753.
Foon, K.., "Biological Response Modifiers: The New Immunotherapy", Cancer Research 1989, 49, 1621-1639.
Aderka et al., "Stabilization of the Bioactivity of Tumor Necrosis Factor by Its Soluble Receptors," J. Exp. Med., 175:323-329, 1992.
Alvaro-Garcia et al., "Cytokines in Chronic Inflammatory arthrities," J. of Immunology, 146:3365-3371, 1991.
Bennett, "The Etiology of Rheumatoid Arthritis," Textbook for Rheumatology, Kelley et al., eds., W. B. Saunders: Philadelphia, Ch. 58, pp. 879-886, 1985.
Beutler et al., Tumor Necrosis Factors: The Molecules and Their Emerging Roles in Medicine, Beutler, ed., Raven Press, New York, 1992. Ch. 2-3, 26.
Beutler et al., "The Biology of Cachectin/TNF--A Primary Mediator of the Host Response," Ann. Rev. Immunol., 7:625-655, 1989.
Bodanszky et al., Peptide Synthesis, John Wiley & Sons, 2d Ed., 1976.
Brennan et al., "Inhibitory Effect of TNF alpha Antibodies on Synovial Cell Interleukin-1 Production in Rheumatoid Arthritis," Lancet, 244-247, 1989.
Buchan et al., "Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1 alpha," Clin. Exp. Immunol., 73:449-455, 1988.
Butera et al., "Regulation of HIV-1 Expression by Cytokine Networks in a CD4.sup.+ Model of Chronic Infection," J. Immunology, 150:625-634, 1993.
Camussi et al., "Tumor necrosis Factor/Cachectin stimulates peritoneal macrophages, polymorphonuclear neutrophils, and vascular endothelial cells to synthesize and release platelet-activating factor," J. Exp. Med., 166:1390-1404, 1987.
Carswell et al., "An endotoxin-induced serum factor that causes necrosis of tumors," Proc. Natl. Acad. Sci. USA, 72:3666-3670, 1975.
Cerami et al., "The role of cachectin/TNF in endotoxic shock and cachexia," Immunol. Today, 9:28-31, 1988.
Debets et al., "The Role of Tumor necrosis Factor/Cachectin in Septic Shock," Second Vienna Shock Forum, 463-466, 1989.
Espevik et al., "A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monoctyes," J. Immunol. Methods, 95:99-105, 1986.
Fiers, "Characterization at the molecular, cellular and in vivo level," FEBS Letters, 285:199-212, 1991.
Goeddel et al., "Tumor Necrosis Factors: Gene Structure and Biological Activities," Spring Harbor Symp. Quant. Biol., LI:597-609, 1986.
Harris, "Rheumatoid Arthritis: The Clinical Spectrum" Textbook of Rheumatology, Kelley et al., eds., W. B. Saunders: Philadelphia, Ch. 60, pp. 915-990, 1985.
Haworth et al., "Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha," Eur. J. Immunol., 21:2575-2579, 1991.
Kent et al., "Modern Methods for the Chemical Synthesis of Biologically Active Peptides," Synthetic Peptides in biology and Medicine, Alitalo et al., eds., Science Publishers: Amersterdam, pp. 29-57, 1985.
Kern et al., "Cancer Cachexia," J. Parent. Enter. Nutr., 12:286-298, 1988.
Kornbluth et al., "Tumor Necrosis Factor Production by Human Monocytes Is a Regulated Event: Induction of TNF-alpha-mediated cellular Cytoxicity by Endotoxin," J. Immunol., 137:2585-2591, 1986.
Kriegler et al., "A Novel Form of TNF/Cachectin Is a Cell Surface Cytotoxic Transmembrane Protein: Ramifications for the Complex Physiology of TNF," Cell., 53:45-53, 1988.
Merrifield, "Solid Phase Peptide Synthesis. I. the Synthesis of a Tetrapeptide," J. Am. Chem. Soc., 15:2149-2154, 1963.
Michie et al., "Tumour necrosis factor and bacterial sepsis," Br. J. Surg., 76:670-671, 1989.
Michie et al., "Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings," Surgery, 104:280-286, 1988.
Michie et al., "Chronic TNF Infusion Causes Anorexia But Not Accelerated Nitrogen Loss," Ann. Surg., 209:19-24, 1989.
Michie et al., "Detection of Circulating Tumor necrosis Factor After Endotoxin Administration," N. Eng. J. Med., 318:1481-1486, 1988.
Oliff, "The Role of Tumor Necrosis Factor (Cachectin) in Cachexia," Cell, 54:141-142, 1988.
Oliff et al., "Tumors Secreting Human TNF/Cachectin Induce Cachexia in Mice," Cell, 50:555-563, 1987.
Piguet et al., "Tumor necrosis factor/Cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease," J. Exp. Med., 166:1280-1289, 1987.
Pober et al., "Two Distinct Monokines, Interleukin 1 and Tumor Necrosis Factor, Each Independently Induce Biosynthesis and Transient Expression of the Same Antigen on the Surface of Cultured Human Vascular Endothelial Cells," J. Immunol., 136:1680-1687, 1986.
Pober et al., "Activation of Cultured Human Endothelial Cells by Recombinant Lymphotoxin: Comparison with Tumor Necrosis Factor and Interleukin 1 Species," J. Immunol., 138:3319-3324, 1987.
Poli et al., "Tumor necrosis factor alpha function in an autocrine manner in the induction of human immunodeficiency virus expression," Proc. Natl. Acad. Sci. USA, 87:782-785, 1990.
Porteu et al., "Shedding of Tumor Necrosis Factor Receptors by Activated Human Neutrophils," J. Exp. Med., 172:599-607, 1990.
Pujol-Borrell et al., "HLA class II induction in human islet cells by interferon-y plus tumor necrosis factor of lymphotoxin," Nature, 326:304-306, 1987.
Revhaug et al., "Inhibition of Cyclo-oxygenase Attentuates the Metabolic Response to Endotoxin in Humans," Arch. Surg., 123:162-170, 1988.
Silva et al., "Prophylactic and Therapeutic Effects of a Monoclonal Antibody to Tumor Necrosis Factor-alpha in Experimental Gram-Negative Shock," J. Infect. Sis., 162:421-427, 1990.
Simpson et al., "Role of Tumor Necrosis Factor in Sepsis and Acute Lung Injury," Crit. Care Clin., 5:27-47, 1989.
Smith et al., "The Active Form of Tumor Necrosis Factor is a Trimer," J. Biol. Chem., 262:6951-6954, 1987.
Stewart et al., Solid Phase Peptide Synthelia, Pierce Chemical Company: Illinois, 1984.
Tracey et al., "Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteramia," Nature, 330:662-664, 1987.
Waage et al., "Association Between Tumour Necrosis Factor in Serum and Fatal Outcome in Patients with Meningococcal Disease," Lancet, 1:355-357, 1987.
Wide, "Solid Phase Antigen-Antibody Systems," Radioimmune Assay Method, Kirkham, ed., E. & S. Livingstone: Edinburgh, pp. 405-412, 1970.
Williams et al., "Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis," Proc. Natl. Acad. Sci. USA, 89:9784-9788, 1992.

Affiliated with

Also associated with

Rating

Tumor necrosis factor inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tumor necrosis factor inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor necrosis factor inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1505657